1. Introduction {#sec1}
===============

Silicone oil is an excellent endotamponade agent for superior breaks and detachments complicated by proliferative vitreoretinopathy (PVR). However, its density, which is lower than water, may result in fluid accumulation in the inferior quadrant, which is not covered by silicone oil, and ineffective tamponade at the retinal breaks \[[@B1]--[@B3]\]. Therefore, an aqueous environment with inflammatory and cellular proliferation may promote development of inferior PVR \[[@B4]--[@B7]\]. Despite improvement of vitreous microsurgical techniques, the surgical treatment of PVR is challenging in vitreoretinal surgery and can lead to blindness and ocular globe atrophy \[[@B3]\].

A high-density silicone oil was developed \[[@B3], [@B8]--[@B12]\] as an endotamponade agent for use in cases of complicated retinal detachments, especially those with inferior PVR.

Heavy silicone oil (HSO) has a high density and is heavier than water. Due to the properties of HSO, it has been proposed for use in treating complicated retinal detachments \[[@B3], [@B13], [@B14]\]. Oxane HD (Bausch & Lomb, Rochester, NY, USA) is a HSO comprised of a mixture of ultrapurified silicone oil (Oxane 5,700 centistokes) and RMN3 (partly fluorinated olefin). The mixture, with a density of 1.02 g/cm^3^, a viscosity of 3,300 mPas, and a refractive index of 1.40, is homogeneous and stable in the presence of water and air and its surface tension is higher than 40 mN/m \[[@B2], [@B3]\]. [Table 1](#tab1){ref-type="table"} shows the HSO chemical and physical properties.

Some authors have reported that HSO is associated with ocular inflammatory reactions, increased intraocular pressure (IOP), cataract formation, and emulsification as well as difficulties to remove the HSO from the eye \[[@B15]--[@B17]\].

Several published studies have analyzed the complications and anatomic success rates after short-term intraocular tamponade with HSO. In most studies, the HSO was removed between 3 and 6 months postoperatively.

The aim of the current study was to evaluate the anatomic outcomes, functional results, and ocular adverse effects in patients with complicated retinal detachments in whom Oxane HD was used as a long-term intraocular endotamponade agent.

2. Methods {#sec2}
==========

We retrospectively studied 25 eyes of 25 patients with complicated retinal detachments by PVR. Patients underwent pars plana vitrectomy (PPV) and injection of Oxane HD as an internal tamponade agent. The surgeries were performed between 2006 and 2013 in the retina sector of the Federal University of São Paulo, São Paulo, and the Brazilian Institute of Fight Against Blindness, Assis, São Paulo, Brazil.

The inclusion criteria were primary or recurrent rhegmatogenous retinal detachments complicated by inferior PVR worse than CA3 \[[@B18]\] and/or complicated by hypotonia in eyes with combined rhegmatogenous and tractional retinal detachment associated with PVR that occurred in the context of diabetic retinopathy associated with retinal breaks due to severe fibrovascular proliferation. All retinal detachments in this study were considered to have a poor prognosis and the probable outcome should be the globe atrophy due to ciliary body traction related to advanced PVR. The follow-up period was at least 6 months.

The exclusion criterion was the presence of a severe systemic disease or inability to undergo regular follow-up examinations.

Patients were advised that the injection of HSO was based on published experience of 3-to-6-month use of this silicone oil as an endotamponade agent in inferior PVR. They were informed that, due to the complex clinical situations and the poor prognosis of the study eyes, HSO was used as a vitreous substitute for longer than the current reported time in the literature. All patients provided their informed consent and have authorized the use of their clinical data in the study.

The preoperative and postoperative data included the medical history, measurement of the BCVA using a Snellen chart, slit-lamp examination, intraocular pressure (IOP) measured by Goldmann tonometry, binocular fundoscopy, B-scan ultrasonography, and fundus photographs.

Follow-up examinations were scheduled for postoperative day 1, week 1, and months 1 and 3 after the initial surgery and every 3 months until the end of the follow-up period. Unscheduled appointments, complications, and additional interventions were documented.

The same vitreoretinal surgeon (Maurício Maia) performed all surgeries using local retrobulbar anesthesia. The surgery included a standard three-port, 23-gauge PPV, phacoemulsification. Retinotomy, retinectomy, and internal limiting peeling were performed if necessary. Endophotocoagulation was performed to treat retinal breaks. Scleral buckling was performed following retinotomies of 180 degrees or more or if there was residual vitreous at the vitreous base at the end of the surgical procedure.

Direct perfluorocarbon-silicone exchange was avoided to prevent "sticky oil" formation; in all patients, the perfluorocarbon liquid was aspirated completely due to a fluid air exchange followed by injection of Oxane HD (HSO) under air.

When the HSO was removed, it was aspirated using a 19-gauge needle BD (Becton Dickinson, USA) connected to an extrusion silicon tube; the needle was inserted by sclerotomy via pars plana and the extrusion silicon tube was changed 2-3 times due to obstruction of the system by the HSO. Many times, a bubble of residual silicon oil was deposited at the posterior pole and such technique of HSO removal is important information for vitreoretinal surgeons that will perform this surgical technique.

The preoperative and final postoperative BCVA levels were analyzed after they were converted to the logarithm of the minimum angle of resolution (logMAR).

The study adhered to the tenets of the Declaration of Helsinki and all federal laws. The ethics committee of our institution approved the study.

A comparison of preoperative and postoperative best-corrected visual acuities at month 1, month 6, and last visit was made in the group in which HSO was removed and in the group in which HSO was not removed. Statistical calculations were performed using the Wilcoxon test to compare the preoperative and postoperative VA levels. *P* \< 0.05 was considered statistically significant. The SPSS (v15.0) statistical package was used for statistical analysis.

3. Results {#sec3}
==========

Twenty-five eyes of 25 patients (19 men, 6 women; mean age, 49 ± 18.2 years; range, 17 to 80 years) were included in this study. The surgeries were performed between March 2006 and June 2013. The mean follow-up time was 21.44 ± 15.28 months.

Seventeen eyes had a rhegmatogenous retinal detachment complicated by inferior PVR; eight eyes had a tractional retinal detachment due to proliferative diabetic retinopathy complicated by retinal breaks and inferior PVR. All eyes included in this study had a macular detachment and also hypotony.

Among the eyes with a rhegmatogenous retinal detachment, one was secondary to toxoplasmosis uveitis, another had a complicated retinal detachment secondary to trauma, and the last one had multiple angiomas secondary to Von Hippel-Lindau disease.

The retinal detachments in all eyes were considered to have a poor prognosis due to the presence of advanced PVR. [Table 2](#tab2){ref-type="table"} shows the detailed patient data and the classifications of PVR \[[@B18]\].

Oxane HD was the primary tamponade agent in eight (32%) eyes. Seventeen (68%) patients had undergone a previous unsuccessful surgery for retinal reattachment and underwent retreatment with Oxane HD due to development of severe PVR after the first surgery. During the first surgery, PPV with injection of octafluoropropane gas (C3F8) was performed in five of these eyes, 1,000-centistoke silicone oil was injected in 10 eyes, and 5,000-centistoke silicone oil was injected in two additional eyes. All the 12 eyes that received silicone oil during the first surgery had a redetachment despite use of an endotamponade agent.

Two eyes (eyes 11 and 16) had undergone a previous PPV associated with scleral buckling in another institution. In three other eyes (12, 13, and 23), scleral buckles were implanted during the retreatment.

Sixteen eyes were phakic and nine were pseudophakic. Among the phakic patients, 14 underwent cataract extraction associated with PPV and two underwent cataract extraction when the HSO was removed.

The HSO was removed from 11 eyes after a mean period of 26.55 ± 21.38 months. In these eyes, the IOP became elevated in four (16%) eyes during the follow-up period. The IOP was uncontrolled in three patients despite instillation of antiglaucomatous eye drops and the HSO was removed and replaced with a 5,000-centistoke silicone oil. The retina remained stable and reattached in all eyes after the HSO was removed. Additional procedures during HSO removal included phacoemulsification (2 eyes), epiretinal membrane (ERM) peeling (1 eye), scleral IOL implantation (1 eye), and secondary IOL implantation (1 eye).

The HSO was left in the eyes of 14 (56%) patients because of the high risk of recurrence of the retinal detachment and ocular globe atrophy. Among these eyes, one had an oil drop in the anterior chamber; however, we elected not to remove the HSO due to the poor prognosis. In another eye, the HSO was not removed due to superior persistent retinal detachment and PVR. Three of these patients needed topical antiglaucomatous eye drops to control the IOP. The mean follow-up period was 11.07 ± 7.44 months.

The mean preoperative logMAR BCVA in the group in which HSO was not removed was 1.90 ± 0.58, which increased significantly to 1.22 ± 0.58 at month 1 (*P* = 0.001) and to 1.07 ± 0.63 at month 6 (*P* = 0.027). Between 6 months and the last visit of follow-up, there was no statistically significant difference in the analysis of BCVA. In the group in which HSO was removed, the mean baseline logMAR BCVA was 1.87 ± 0.63 which increased significantly to 1.33 ± 0.74 at month 1 (*P* = 0.008). Between the first month and the last visit, there was no statistically significant difference in BCVA ([Table 3](#tab3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).

Ten (40%) eyes had cells in the anterior chamber without hypopyon or keratic precipitates during the first postoperative month. Inflammatory reactions resolved in all eyes with topical steroids within 15 days.

Oil emulsification occurred in 52% of the eyes. Complications such as development of an ERM during Oxane HD tamponade occurred in one (4%) eye. Lens opacity progressed in all phakic patients, and they underwent cataract surgery at the same time the HSO was removed. [Table 2](#tab2){ref-type="table"} lists the other complications.

Anatomic success was achieved in 92%. One eye had a recurrence of the rhegmatogenous retinal detachment and another eye had a persistent tractional retinal detachment. No additional surgeries were performed in these cases due to the poor prognosis and risk of ocular globe atrophy.

4. Discussion {#sec4}
=============

In this retrospective study, we described the effects of HSO as an endotamponade agent for complicated retinal detachments with inferior PVR. Despite advances in PPV techniques, vitreoretinal surgeons are still challenged by complex retinal detachments complicated by PVR.

Standard silicone oil is an excellent tamponade agent for most retinal detachments \[[@B4], [@B19], [@B20]\]. However, the tamponade of the inferior retina may be unsatisfactory since the density of standard silicone oil is lower than water. This results in an aqueous inflammatory environment that may predispose and increase the possibility of inferior PVR development \[[@B10]--[@B12]\]. In such eyes, the use of HSO has been suggested to be effective and safe for the treatment of inferior retina \[[@B8]--[@B14]\].

Most studies about the use of HSO in complex retinal detachments report that the HSO remained in the eye for an average of 3 to 6 months \[[@B2], [@B9], [@B10], [@B21], [@B22]\]. We studied eyes with a poor prognosis due to complex retinal detachments and extensive inferior PVR. Because of the severity of the retinal detachments, we left the HSO in the eyes for longer than 3 to 6 months and observed the effects of HSO over time.

Among the 25 eyes studied, the silicone oil has not been removed from 14 eyes due to the complexity of the cases. These patients had the HSO in situ for a mean period of 11.07 ± 7.44 months. The HSO was removed from 11 eyes after a mean of 26.55 ± 21.38 months. To our knowledge, such study is unique because no published studies have reported the effects of HSO in situ for as many months as in the current study.

Another factor in the current study that has not been reported in other series is the use of HSO in cases of tractional retinal detachments due to proliferative diabetic retinopathy with associated retinal tears and development of inferior PVR. We included eight patients with combined tractional and rhegmatogenous retinal detachment secondary to diabetic retinopathy. These eyes did not have higher complication rates compared with patients with a rhegmatogenous retinal detachment.

We observed a high anatomic success rate (defined in this current series as success until 6 months of follow-up) in eyes with primary complex retinal detachment and recurrent retinal detachment. Eight eyes in which HSO was used as a primary endotamponade agent had an anatomic success rate of 100%. Seventeen (68%) eyes had undergone a previous unsuccessful surgery for retinal reattachment and underwent a second surgery with injection of HSO. One eye had a persistent retinal detachment resulting from severe tractional retinal detachment secondary to diabetes retinopathy and PVR. Another eye had a recurrent rhegmatogenous retinal detachment despite retreatment and HSO tamponade. Thus, we achieved an anatomic success rate of 92% when we analyzed the data from the 25 eyes from this series.

Despite the final low VA due to the severity of the cases, there was statistical improvement in BCVA in the group that did not remove the HSO and in the group in which HSO was removed. The BCVA in the group in which HSO was not removed improved significantly during the first 6 months and remained stable until the end of follow-up. Among the eyes that had the oil removed, there was improvement in BCVA after 1 month which remained stable until the last visit (*P* \< 0.05).

Previous studies have reported an intraoperative common complication related to an interaction between the HSO and perfluorocarbon. When these substances come into contact intraoperatively, a hyperviscous solution that is described as "sticky oil" forms \[[@B23]\]. Thus, direct perfluorocarbon-silicone exchange should not be performed. In the current study, three patients had a giant tear. In these cases, such as in all eyes submitted to intravitreal HSO injection, fluid-air exchange followed by injection of HSO was performed successfully.

Some authors consider HSO to be poorly tolerated intraocularly, leading to early removal of oil (3--6 months). The well-known effects of this tamponade agent are cataract formation, oil emulsification, ocular hypertension, proinflammatory response, macular ERMs, and high levels of intraocular pressure (IOP) \[[@B16]\]. A previous study that evaluated the tolerance and efficacy of Oxane HD as an internal tamponade for retinal detachment surgery reported that Oxane HD was well tolerated and did not appear to have proinflammatory effects \[[@B3]\].

A recent study analyzed 61 eyes and compared Densiron (Densiron-68, Fluoron Company, Neu-Ulm, Germany) and a normal density 1,000-centistoke silicone oil. The study reported similar complication rates of cataract formation, elevated IOP, inflammatory reaction, macular ERMs, and silicone oil emulsification \[[@B24]\].

We observed inflammation in the anterior chamber in 40% of eyes, which is similar to other reported studies in which Oxane HD was used \[[@B25]\]. Emulsification occurs earlier with HSOs (Oxane HD and Densiron) than with standard silicone oils \[[@B3], [@B8], [@B16]\]. In the current study, HSO emulsification occurred in 13 (52%) patients at a long-term follow-up. However, despite the HSO emulsification, these eyes required silicon oil tamponade to avoid PVR progression, hypotony, and globe atrophy. New interventions and silicon oil change may be also alternatives for management of such complications \[[@B3], [@B8]\]; however, the surgeon must be aware of the possibility of globe atrophy and BCVA decrease due to ischemic optic neuropathy \[[@B16]\]; so the risks versus benefits may be analysed before such decision for each specific case.

Similar to other studies, the IOP was elevated in 16% of patients in whom Oxane HD was injected \[[@B2], [@B11], [@B13]\]. Despite previous reports of high rates of IOP elevations in patients injected with HSO, the most recent data showed equivalent rates of IOP elevation when Oxane HD and Densiron were compared with standard silicone oil \[[@B24], [@B25]\].

5. Conclusion {#sec5}
=============

In summary, this retrospective study found that HSO is an effective tamponade agent in both complex rhegmatogenous and tractional retinal detachments complicated by PVR.

Most patients had a good anatomic success rate with improved vision. Despite the high rates of HSO emulsification, it is possible to maintain the HSO in eyes for long periods with relative tolerability and safety resulting in useful vision for specific cases.
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###### 

Physical properties of Oxane HD.

  -- --------------------------------------------------
     Viscosity 3,800 centistokes (3,300 mPas at 25°C)
     Density 1.03 g/cm^3^ at 25°C
     Refractive index 1.40
     Volatility \<0.1%
     Surface tension \>40 mN/m
     RMN3 volume 11.9
  -- --------------------------------------------------

###### 

Pre- and postoperative records per patient.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Indication   Age/ \   Lens status   Follow-up (months)   TA in the 1st surgery   PVR    TA in retreatment   Baseline VA (Snellen)   Final VA (Snellen)   Baseline IOP (mmHg)   Final IOP (mmHg)   Biomicroscopy findings                                                 Time of HSO removal (months)   Redetachment   Comments
                         gender                                                                                                                                                                                                                                                                                                    
  --------- ------------ -------- ------------- -------------------- ----------------------- ------ ------------------- ----------------------- -------------------- --------------------- ------------------ ---------------------------------------------------------------------- ------------------------------ -------------- ---------------------------------------------------------------------------------------
  1         RRD          61/M     Pseudo        22                   1000 cts SO             CP6    Oxane HD            20/200                  20/40                16                    14                 Inflammatory cells in the AC, 1st month, KP in endothelium,6th month   6                              No             Oil emulsification

  2         RRD          53/F     Pseudo        18                   C3F8 gas                CP3    Oxane HD            HM                      HM                   15                    15                 Normal                                                                 36                             No             Ischemic optic nerve neuropathy; oil exchange due to IOP elevated; oil emulsification

  3         RRD          57/M     Phakic        24                   C3F8 gas                CA3    Oxane HD            HM                      20/200               12                    12                 Inflammatory cells in the AC, 1st month                                11                             No             Ischemic optic nerve neuropathy; oil emulsification

  4         RRD          63/F     Phakic        30                   1000 cts SO             CP2    Oxane HD            LP                      HM                   10                    13                 Oil in the AC, 6th month                                               36                             No             Oil emulsification

  5         RRD          28/M     Phakic        36                   C3F8 gas                CA6    Oxane HD            20/400                  20/200               16                    15                 KP in endothelium and cells in the AC, 1st month                       17                             No             IOL fixation

  6         RRD          22/F     Phakic        42                   Oxane HD                CP1    NA                  20/200                  20/25                15                    9                  Normal                                                                 48                             No             RD secondary to Toxoplasmosis

  7         RRD          80/F     Phakic        24                   5000 cts SO             CP8    Oxane HD            HM                      CF 2m                17                    16                 KP in endothelium and cells in the AC, 1st month                       NR                             Yes            Giant tear; redetachment; oil emulsification

  8         RRD          66/M     Phakic        24                   Oxane HD                CA3    Oxane HD            HM                      20/63                10                    12                 Normal                                                                 8                              No             Epiretinal membrane; oil emulsification

  9         RRD          62/M     Phakic        70                   1000 cts SO             NA     Oxane HD            20/400                  20/100               14                    12                 Normal                                                                 72                             No             Oil exchange due to IOP elevated; oil emulsification

  10        RRD          41/M     Phakic        6                    Oxane HD                CP3    NA                  CF 3m                   20/80                13                    13                 Normal                                                                 NR                             No              

  11        RRD          66/M     Pseudo        12                   5000 cts SO             CA10   Oxane HD            20/200                  20/80                21                    12                 Normal                                                                 NR                             No              

  12        RRD          21/M     Phakic        12                   Oxane HD                CA3    NA                  HM                      20/200               15                    16                 Inflammatory cells in the AC, 1st month                                NR                             No             RD secondary to open ocular trauma

  13        RRD          62/M     Pseudo        12                   Oxane HD                CP3    Oxane HD            20/200                  20/80                14                    17                 Inflammatory cells in the AC, 1st month                                NR                             No             Oil emulsification

  14        RRD          68/M     Pseudo        6                    1000 cts SO             CP2    Oxane HD            CF 1m                   20/40                18                    18                 Inflammatory cells in the AC, 1st month                                NR                             No              

  15        RRD          54/M     Phakic        6                    1000 cts SO             CP1    Oxane HD            CF 3m                   20/32                24                    17                 Inflammatory cells in the AC, 1st month                                NR                             No              

  16        RRD          20/F     Phakic        8                    1000 cts SO             CP3    Oxane HD            LP                      CF 1m                22                    14                 Normal                                                                 NR                             No             Von Hippel-Lindau

  17        RRD          64/M     Phakic        7                    1000 cts SO             CP8    Oxane HD            CF 1m                   20/80                23                    13                 Inflammatory cells in the AC, 1st month                                NR                             No             Intraoperative bleeding in the first surgery

  18        TRD          56/M     Phakic        20                   C3F8 gas                CP4    Oxane HD            CF 1m                   20/80                13                    20                 Normal                                                                 6                              No             Oil emulsification

  19        TRD          24/M     Pseudo        44                   C3F8 gas                NA     Oxane HD            HM                      CF 3m                14                    14                 Normal                                                                 46                             No             Optical nerve atrophy; oil emulsification

  20        TRD          49/M     Pseudo        34                   Oxane HD                CA10   5000 cts SO         LP                      HM                   14                    15                 Normal                                                                 6                              No             Oil exchange due to IOP elevated; oil emulsification

  21        TRD          63/F     Phakic        13                   1000 cts SO             CA10   Oxane HD            LP                      HM                   12                    14                 Normal                                                                 NR                             Yes            Ischemic optic nerve neuropathy and persistent retinal detachment

  22        TRD          29/M     Pseudo        36                   Oxane HD                CA1    NA                  HM                      20/400               18                    11                 Normal                                                                 NR                             No             Oil emulsification

  23        TRD          17/M     Pseudo        12                   1000 cts SO             CA3    Oxane HD            CF 1m                   20/80                17                    10                 Oil emulsification, 6th month                                          NR                             No             Oil emulsification

  24        TRD          39/M     Phakic        12                   Oxane HD                CA10   NA                  LP                      HM                   11                    20                 Normal                                                                 NR                             No             Ischemic optic nerve neuropathy

  25        TRD          60/M     Phakic        6                    1000 cts SO             CP3    Oxane HD            CF 1m                   20/200               25                    18                 Inflammatory cells in the AC, 1st month                                NR                             No              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RRD = rhegmatogenous retinal detachment; TRD = tractional retinal detachment; F = female; M = male; TA = tamponade agent; PVR = proliferative vitreoretinopathy; VA = visual acuity; IOP = intraocular pressure; SO = silicone oil; HSO = heavy silicone oil; HM = hand motion; CF = count fingers; LP = light perception; AC = anterior chamber; KP = keratic precipitates; IOL = intraocular lens; RD = retinal detachment; NR = not removed, Pseudo = pseudophakic; NA = not available; cts = centistokes.

###### 

Comparison between LogMAR BCVA at baseline, month 1, month 6, and final in patients in whom HSO was removed and patients in whom HSO was not removed.

                               Baseline   Month 1   Month 6   Final
  ---------------------------- ---------- --------- --------- -------
  HSO not removed (*n* = 14)                                   
   Mean                        1.90       1.22      1.07      1.03
   SD                          0.58       0.58      0.63      0.66
   Median                      1.79       1.15      0.80      0.80
   Min                         1.00       0.60      0.49      0.20
   Max                         2.70       2.20      2.20      2.20
                                                              
  HSO removed (*n* = 11)                                       
   Mean                        1.87       1.33      1.24      1.11
   SD                          0.63       0.74      0.80      0.79
   Median                      2.20       1.00      1.00      1.00
   Min                         1.00       0.30      0.20      0.09
   Max                         2.70       2.20      2.20      2.20

Patients in whom HSO was not removed.

Baseline \> month 1 (*P* = 0.001), month 6 (*P* = 0.001), and final (*P* = 0.001).

Month 1 \> month 6 (*P* = 0.027), final (*P* = 0.027).

Month 6 = final (*P* = 0.180).

Patients in whom HSO was removed.

Baseline \> month 1 (*P* = 0.008), month 6 (*P* = 0.008), and final (*P* = 0.005).

Month 1 = month 6 (*P* = 0.068); month 1\> final (*P* = 0.028).

Month 6 = final (*P* = 0.068).
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